New work from two groups advances tools to model the blood-brain barrier and could improve the way drugs are delivered for brain diseases. This builds on our ability to study, and eventually treat, Huntington’s disease.
Researchers with PTC Therapeutics recently published exciting new findings - a promising new huntingtin lowering drug that can be taken as a pill. Will this change how we move forward with huntingtin lowering?
Voyager Therapeutics is shifting towards a new technology to deliver gene therapy and away from a planned HD clinical trial. But this could lead to less invasive drugs in the long run, and many other companies are working on HD gene therapies.
Researchers design a virus to more effectively deliver gene-silencing drugs throughout the brain.
New research reveals blood vessel changes that could contribute to problem in HD
Roche's 'brain shuttle' sneaks drugs past the blood-brain barrier. Could it work for HD gene silencing drugs?
Damage to cells caused by oxidative stress is part of HD - could a new targeted drug help reduce this problem?
Positive results from tests of a new 'KMO inhibiting' drug in Huntington's disease mice